BACKGROUND AND PURPOSE: Human parathyroid hormone (PTH) is critical for maintaining physiological calcium homeostasis and plays an important role in the formation and maintenance of the bone. Full-length PTH and a truncated peptide form are approved for treatment of hypoparathyroidism and osteoporosis respectively. Our initial goal was to develop an improved PTH therapy for osteoporosis, but clinical development was halted. The novel compound was then repurposed as an improved therapy for hypoparathyroidism. EXPERIMENTAL APPROACH: A longer-acting form of PTH was synthesised by altering the peptide to increase cell surface residence time of the bound ligand to its receptor. In vitro screening identified a compound, which was tested in an animal model of osteoporosis before entering human trials. This compound was subsequently tested in two independent animal models of hypoparathyroidism. KEY RESULTS: The peptide identified, LY627-2K, exhibited delayed internalization kinetics. In an ovariectomy-induced bone loss rat model, LY627-2K demonstrated improved vertebral bone mineral density and biomechanical properties at skeletal sites and a modest increase in serum calcium. In a Phase I clinical study, dose-dependent increases in serum calcium were reproduced. These observations prompted us to explore a second indication, hypoparathyroidism. In animal models of this disease, LY627-2K restored serum calcium, comparing favourably to treatment with wild-type PTH. CONCLUSIONS AND IMPLICATIONS: We summarize the repositioning of a therapeutic candidate with substantial preclinical and clinical data. Our results support its repurposing and continued development, from a common indication (osteoporosis) to a rare disease (hypoparathyroidism) by exploiting a shared molecular target. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
BACKGROUND AND PURPOSE:Humanparathyroid hormone (PTH) is critical for maintaining physiological calcium homeostasis and plays an important role in the formation and maintenance of the bone. Full-length PTH and a truncated peptide form are approved for treatment of hypoparathyroidism and osteoporosis respectively. Our initial goal was to develop an improved PTH therapy for osteoporosis, but clinical development was halted. The novel compound was then repurposed as an improved therapy for hypoparathyroidism. EXPERIMENTAL APPROACH: A longer-acting form of PTH was synthesised by altering the peptide to increase cell surface residence time of the bound ligand to its receptor. In vitro screening identified a compound, which was tested in an animal model of osteoporosis before entering human trials. This compound was subsequently tested in two independent animal models of hypoparathyroidism. KEY RESULTS: The peptide identified, LY627-2K, exhibited delayed internalization kinetics. In an ovariectomy-induced bone lossrat model, LY627-2K demonstrated improved vertebral bone mineral density and biomechanical properties at skeletal sites and a modest increase in serum calcium. In a Phase I clinical study, dose-dependent increases in serum calcium were reproduced. These observations prompted us to explore a second indication, hypoparathyroidism. In animal models of this disease, LY627-2K restored serum calcium, comparing favourably to treatment with wild-type PTH. CONCLUSIONS AND IMPLICATIONS: We summarize the repositioning of a therapeutic candidate with substantial preclinical and clinical data. Our results support its repurposing and continued development, from a common indication (osteoporosis) to a rare disease (hypoparathyroidism) by exploiting a shared molecular target. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
Authors: Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Chiyuan Zhang; Rebecca Ives; Amanda Tulley; James Sliney; Serge C Cremers; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2012-11-15 Impact factor: 5.958
Authors: Yanfei L Ma; Qing Q Zeng; Leah L Porras; Anita Harvey; Terry L Moore; Timothy L Shelbourn; Gail P Dalsky; Thomas J Wronski; J Ignacio Aguirre; Henry U Bryant; Masahiko Sato Journal: Endocrinology Date: 2011-02-22 Impact factor: 4.736
Authors: Karen K Winer; Ninet Sinaii; James Reynolds; Donna Peterson; Karen Dowdy; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: Karen K Winer; Chia Wen Ko; James C Reynolds; Karen Dowdy; Meg Keil; Donna Peterson; Lynn H Gerber; Charles McGarvey; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Jun Guo; Ashok Khatri; Akira Maeda; John T Potts; Harald Jüppner; Thomas J Gardella Journal: J Bone Miner Res Date: 2016-09-09 Impact factor: 6.741
Authors: Todd A Theman; Michael T Collins; David W Dempster; Hua Zhou; James C Reynolds; Jaime S Brahim; Paul Roschger; Klaus Klaushofer; Karen K Winer Journal: J Bone Miner Res Date: 2009-05 Impact factor: 6.741
Authors: A B Abou-Samra; H Jüppner; T Force; M W Freeman; X F Kong; E Schipani; P Urena; J Richards; J V Bonventre; J T Potts Journal: Proc Natl Acad Sci U S A Date: 1992-04-01 Impact factor: 11.205
Authors: Alex R B Thomsen; Bianca Plouffe; Thomas J Cahill; Arun K Shukla; Jeffrey T Tarrasch; Annie M Dosey; Alem W Kahsai; Ryan T Strachan; Biswaranjan Pani; Jacob P Mahoney; Liyin Huang; Billy Breton; Franziska M Heydenreich; Roger K Sunahara; Georgios Skiniotis; Michel Bouvier; Robert J Lefkowitz Journal: Cell Date: 2016-08-04 Impact factor: 41.582
Authors: Maira L Mendonça; Francisco A Pereira; Marcello H Nogueira-Barbosa; Lucas M Monsignore; Sara R Teixeira; Plauto Ca Watanabe; Lea Mz Maciel; Francisco Ja de Paula Journal: BMC Endocr Disord Date: 2013-01-03 Impact factor: 2.763
Authors: Venkatesh Krishnan; Yanfei L Ma; Catherine Z Chen; Natasha Thorne; Heather Bullock; Gregory Tawa; Christy Javella-Cauley; Shaoyou Chu; Weiming Li; Wayne Kohn; Mary D Adrian; Charles Benson; Lifei Liu; Masahiko Sato; Wei Zheng; Andre M Pilon; N Nora Yang; Henry U Bryant Journal: Br J Pharmacol Date: 2017-11-28 Impact factor: 8.739